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2020.101303The rapid and global spread of a new human coronavirus (SARS-CoV-2) has pro-
duced an immediate urgency to discover promising targets for the treatment of
COVID-19. Drug repositioning is an attractive approach that can facilitate the
drug discovery process by repurposing existing pharmaceuticals to treat illnesses
other than their primary indications. Here, we review current information concern-
ing the global health issue of COVID-19 including promising approved drugs and
ongoing clinical trials for prospective treatment options. In addition, we describe
computational approaches to be used in drug repurposing and highlight examples
of in silico studies of drug development efforts against SARS-CoV-2.
INTRODUCTION
Over the past few centuries, outbreaks caused by bacteria like Yersinia pestis and Vibrio cholerae (the caus-
ative agents of plague and cholera, respectively, Cohn and Kutalek, 2016; Pechous et al., 2016) and also by
viral infectious agents such as influenza viruses, Ebola viruses, SARS-CoV-1, MERS-CoV, the Zika virus, and
lately, SARS-CoV-2, have undermined public trust in the ability of modern science to predict and prevent
global pandemic threats. Accordingly, studying historical epidemics can help us identify patterns of viral
outbreaks and design a plan to prepare for the next pandemic. For example, if the unusual influenza-
like illness from February to August 1918 was considered a harbinger, then perhaps the 1918 Spanish flu
pandemic could have resulted in fewer casualties (Simonsen et al., 2018). An overview of the deadliest his-
torical pandemics from Antonine Plague in 165 CE to the ongoing COVID-19 (coronavirus disease-2019)
pandemic, based on data from the World Health Organization (WHO) and US Centers for Disease Control
and Prevention, is illustrated in Figure 1 and includes the dates, natural reservoir host, and the number of
mortalities.
In December 2019, rumors began to spread about the prevalence of a new unknown pneumonia-like illness
in Wuhan, the capital of Hubei Province in the People’s Republic of China. Soon afterward, authorities re-
ported a novel coronavirus as the causative agent of clusters of the new illness (WHO, February 11, 2020).
COVID-19 was the name that the WHO designated for the disease caused by the novel coronavirus, desig-
nated 2019-nCoV and later severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Gorbalenya,
2020). Since the beginning of the outbreak, infections have expanded rapidly into multiple simultaneous
epidemics worldwide. At the time of writing, over 7.2 million confirmed COVID-19 cases and over
410,000 COVID-19-related deaths have been reported across more than 180 countries (https://
coronavirus.jhu.edu/map.html).
The geographical distribution of COVID-19 covers all continents except Antarctica. Epidemiologists inWu-
han believe the Huanan Seafood Wholesale Market in Wuhan to be the point of origin of SARS-CoV-2, due
to its connection to the trading of live wild animals (WHO January 22, 2020) (Zhou et al., 2020a). COVID-19 is
highly contagious, with a basic reproduction number (R0) of between 1.4 and 6.5, and can be easily spread
through coughs and sneezes, talking to infected persons, and touching the eyes, nose, or mouth after
touching a contaminated surface (Liu et al., 2020).
SARS-CoV-2 has been found in stool and blood samples (Chen et al., 2020b; Tang et al., 2020), but
the rate of transmission (Chan et al., 2020; Rothe et al., 2020), period of infectivity (Zou et al., 2020),
and duration of viral shedding (Zhou et al., 2020a) are various and uncertain. Large-scale serologic
screening provides a better picture of statistics related to asymptomatic infections for epidemiologic
analysis.iScience 23, 101303, July 24, 2020 ª 2020 The Author(s).
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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l SARS 770 (1year)
MERS 850 (ongoing)
Ebola 11.3k (2years)
Yellow fever 200k (1years)
Swine flu 200k (1years)
18th Century Black plague 600k (ND)
Russian flu 1M (1years)
Cholera 6 outbreak 1M (1years)
Japanese smallpox pandemic 1M (2years)
Hong Kong flu 1M (4years)
Asian flu 1M (1years)
17th Century Black plague 3M (ND)
Antonine plague 5M (15years)
3rd Plague 12M (ND)
HIV/AIDS 25-35M (Ongoing)
Plague of Justinian 30-50M (1year)
Spanish flu 40-50M (1year)
Smallpox 56M (ND)

































Figure 1. Deadliest Pandemics and Outbreaks in Recorded History
Left: Pandemic clock, a comprehensive illustration of the most deadly pandemics through the history sorted by date. Right: Pandemic outbreaks and natural
reservoir hosts sorted by the number of mortalities. In some outbreaks, the exact duration is not precisely determined (ND) because the outbreak died out




ReviewThe phylogeny, virology, and epidemiology of SARS-CoV-2 is being studied extensively. At the genome
level, SARS-CoV-2 has 79.5% homology to SARS-CoV-1, the causative agent of SARS in south China;
85%–96% identity with bat-SL-CoVZC45 (Li et al., 2005), a bat SARS-like coronavirus (Xiao et al., 2020);
and 91.02% similarity with SARS-CoV-2-like coronavirus in pangolin named Pangolin-CoV (Yu et al.,
2020). A population genetic analysis of 103 SARS-CoV-2 genomes from China revealed that the causative
agent of COVID-19 consists of two evolution types. Type L (70% prevalence in Wuhan), which is derived
from the ancestral type S (30% prevalence in Wuhan), is more aggressive and contagious (Tang et al.,
2020b). Zhou et al. investigated the COVID-19 agent through full genome sequencing and phylogenetic
analysis, classifying it as a betacoronavirus (a positive-sense, single-stranded RNA virus), the same subge-
nus as SARS-CoV as well as several bat coronaviruses (Zhou et al., 2020b). In addition, they proved that
SARS-CoV-2 uses the same receptor binding (angiotensin-converting enzyme 2 [ACE2]) and cell entry
pathway as SARS-CoV-1. When compared with SARS-CoV-1, MERS-CoV is less closely related to SARS-
CoV-2 (Lu et al., 2020; Zhu et al., 2020).
Taken together, there is an urgent need for COVID-19 therapeutics due to the S-shaped curve expansion of
the infections, widespread pandemic status, and global burden. Given the similarities between SARS-CoV-
2 and other coronaviruses, and its relative ease of sample acquisition and study, it has been widely
accepted that drug repositioning is a promising approach to make available an effective, safety-assured
treatment in a timely manner. In this review, we summarize diagnostic approaches, risk groups, available
treatment options, and drug repositioning studies related to COVID-19.
DIAGNOSTIC APPROACHES AND MEDICAL COMORBIDITIES
Before efficient treatment, precise diagnosis and classification of patients based on disease severity and
their probable vulnerability to COVID-19 is crucial. Diagnosis has several steps that can be prioritized
based on the provision of facilities during an outbreak. Generally, evaluation of symptoms and particular




Reviewcomplementary test is done to confirm the infection. Clinical manifestations can help to classify patients
and categorize efficient remedies for each cohort.
At the beginning, due to the unknown nature of this emergent virus, all diagnosis was based purely on clin-
ical and radiographic findings (i.e., bilateral infiltrates on chest imaging), failure of antibiotic therapy, and
exclusion of other common respiratory infections (Huang et al., 2020; Zhu et al., 2020). Now, laboratory
detection includes next-generation sequencing platforms, reverse-transcription polymerase chain reaction
(RT-PCR), and serological methods like enzyme-linked immunoassay. Generally, a patient should be taken
into account for laboratory detection if his or her clinical manifestations and/or radiographical records are
positive. From the most common symptoms to the least—these are not constant—for COVID-19 fever, fa-
tigue, dry cough, anorexia, myalgias, dyspnea, and sputum production are known so far (Wang et al.,
2020b). Recently, anosmia and dysgeusia have been added to this list as common symptoms (Giacomelli
et al., 2020). In addition, some less common complaints are headache, sore throat, rhinorrhea, and gastro-
intestinal disorders (e.g., nausea and diarrhea) (Chen et al., 2020a).
Another procedure that is being used to confirm the infection is monitoring laboratory features that are
associated with worse outcomes. A positive correlation has been reported in worse cases between
COVID-19 and sex (the rate of death for males was significantly more than that for females in China and
Italy) (Liang et al., 2020; Onder et al., 2020), lymphopenia, eosinopenia, elevation of liver enzymes, escala-
tion of lactate dehydrogenase, increase of inflammatory markers, rise of D-dimer (>1 mg/mL), elevated pro-
thrombin time, elevation of troponin, increase in creatine phosphokinase levels, and also acute kidney
injury (Guan et al., 2020). Several studies have been conducted to determine the risk groups for severe
illness by SARS-CoV-2. People of any age cannot be excluded, but it is more associated with advanced
age and medical comorbidities including cardiovascular disease, diabetes mellitus, hypertension, chronic
lung disease, cancer, and chronic kidney disease (Zhou et al., 2020a).
Considering antihypertensive medications, there are advocates for both use and cessation of consump-
tion. It is still unclear whether the high mortality rate of patients with hypertension comorbidity is due to
the pathology of disorder or the treatment used to cure it such as ACE inhibitors and angiotensin receptor
blockers (ARBs). ACE2 has been shown to be a co-receptor for viral entry and pathogenesis of SARS-CoV (Li
et al., 2003). There is considerable evidence that shows the escalated expression level of ACE2 in the heart,
brain, and even in urine after treatment with ARBs; however, there is limited evidence showing changes in
serum or pulmonary ACE2 levels (Patel and Verma, 2020; Zhang et al., 2020c). In addition, serological,
radiological, and histomorphological similarities of COVID-19-associated acute respiratory distress syn-
drome (ARDS) and connective tissue disease-associated interstitial lung disease (CTD-ILD) propose the
postulation of triggering or simulating a form of organ-specific autoimmunity in predisposed patients.
Also, some patients showed high-titer antiphospholipid antibodies, including anticardiolipin antibodies
and anti-b2 glycoprotein antibodies (Zhang et al., 2020d). The immunosuppressive therapy in identified pa-
tients with autoantibodies may prevent the development of respiratory failure.PROMISING APPROVED DRUGS AND AVAILABLE CLINICAL TRIALS FOR PROSPECTIVE
TREATMENT OPTIONS OF COVID-19
With regard to treatment, immunological and pharmaceutical investigations are still ongoing. No specific
therapy for COVID-19 is approved by the US Food and Drug Administration (FDA) so far, but many previ-
ously approved drugs, as an efficient approach to drug discovery named drug repurposing, are being
tested on COVID-19. At the time of writing, 1,137 interventional studies have been registered in
ClinicalTrials.gov (https://clinicaltrials.gov/) related to COVID-19, and this number is increasing progres-
sively (Table S1). In particular, the ongoing clinical trials sponsored by the WHO named Solidarity will
compare different treatment options, namely, remdesivir, lopinavir/ritonavir dual treatment, lopinavir/rito-
navir dual treatment with interferon beta 1-alpha, and chloroquine or hydroxychloroquine (paused tempo-
rarily due to the concerns raised about the safety of the drug) against standard of care. As of May 10, 2020,
more than 100 countries have been confirmed to contribute in this investigation.
The interventional drugs in clinical trials can be classifiedbased on their nature and complementary effect. In this
regard, antivirals, antiparasitic drugs, immunosuppressors, immunomodulators, some well-known drugs, and
nutritional drugs, in addition to combination therapies, are considered on ongoing studies for treatment, sup-




Review(Table 1), but many drugs are discovered for a specific disease and repurposed later for another disorder. Fig-
ure 2 illustrates a general path that is being traversed by clinicians these days, although the results may not be
desirable in some cases due to the emergent nature of SARS-CoV-2.
Before clinical manifestations for COVID-19, a significant viral amplification occurs, which subsequently
leads to mild symptoms. Later, at the end stage of infection, severe symptoms are mostly due to the inflam-
matory cell infiltration and inflammatory cytokine storm, which cause acute lung injury, ARDS, and death
(Zhang et al., 2020c). Accordingly, the treatment strategy depends on the stage of the disease or a com-
bination therapy might be considered. Also, it has been suggested that the drugs with both antiviral
and anti-inflammatory properties could be taken into account for COVID-19 clinical trials including barici-
tinib, ruxolitinib, and fedratinib (Stebbing et al., 2020).
As examples of the most common treatment options, chloroquine and hydroxychloroquine, both antima-
larial agents with anti-inflammatory and immunomodulatory activities, have shown inhibitory activity for
SARS-CoV-2 similar to previous studies on SARS-CoV-1 and MERS-CoV (Sanders et al., 2020). These two
treatments are being investigated for use by patients with COVID-19 based on positive in vitro and limited
clinical data. In addition, azithromycin, a macrolide antibiotic, was found to raise the efficacy of hydroxy-
chloroquine as a complementary therapy (Gautret et al., 2020).
Preclinical investigations proved the benefit of lopinavir/ritonavir combination therapy against COVID-19. Lopi-
navir is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, and in a fixed-dose combination with
ritonavir, it is a potent CYP3A4 inhibitor that boosts lopinavir concentrations, could block the main protease of
SARS-CoV-1, and inhibits viral replication (Ratia et al., 2008). This combination is being considered as a remedy
for COVID-19, but complementary research has failed to confirm the results (Cao et al., 2020).
Remdesivir, an investigational monophosphoramidate prodrug of an adenosine analog, was developed
between 2014 and 2016 in response to Ebola (Tchesnokov et al., 2019). Similar to its promising effect on
SARS-CoV-1 andMERS-CoV, remdesivir has displayed potent in vitro activity against SARS-CoV-2 by acting
as an RNA chain terminator by binding to the RNA-dependent RNA polymerase (RdRp) (Wang et al.,
2020a). Although, two recent clinical trials have showed that remdesivir was not associated with dramatic
clinical improvement, many clinical trials are underway (Beigel et al., 2020; Wang et al., 2020c).
Tocilizumab, a humanized monoclonal antibody, inhibits all forms of interleukin-6 (IL-6) receptors (mem-
brane bound or soluble). Tocilizumab was first approved for rheumatoid but was later considered as a com-
plementary treatment in cytokine-release syndrome disease (Kotch et al., 2019). Tocilizumab can diminish
the effect of cytokine storming, including IL-6, which is associated with severe outcomes in patients with
COVID-19 (Zhou et al., 2020a).
Several reports of clinical trials currently underway, but not yet peer-reviewed, have claimed that convales-
cent plasma from recovered patients displays neutralizing activity, which could be transferred to recipients
by plasma infusion (Shen et al., 2020). In addition, monoclonal antibodies against the receptor-binding
domain of the spike protein derived from convalescent patients have displayed neutralizing activity in a
pseudovirus model and also protected against reinfection in animal models after recovery and re-chal-
lenge (Bao et al., 2020; Ju et al., 2020).
Recently, a new promising success was reported. A group of scientists claimed that human recombinant
soluble ACE2 (hrsACE2) can block early stages of SARS-CoV-2 infections (Monteil et al., 2020). ACE2 seems
to be a key and common receptor for many coronaviruses as it was reported to be previously critical for
SARS-CoV-1 and non-critical for MERS-CoV, and now it is introduced as a crucial receptor for SARS-
CoV-2 (Kuba et al., 2005; Müller et al., 2012). Accordingly, preventing the interaction of SARS-CoV-2 and
ACE2 is proposed as a treatment for patients with COVID-19; however, it is not clear whether hrsACE2
can block the growth of SARS-CoV-2.
A new observation explains the international differences in COVID-19 impact by finding positive correlation
between the lack of universal policies of Bacillus Calmette-Guerin (BCG) childhood vaccination (Italy,
Netherlands, the United States) and the severity of COVID-19; however, this has not been confirmed by
the WHO so far (WHO, 2020).4 iScience 23, 101303, July 24, 2020
Drug Brand Name Mechanism of Action Main Indication
Antivirals
Danoprevir Ganovo NS3/4A protease inhibitor HCV
Favipiravir Avigan Nucleoside analog Broad-spectrum antiviral
Lopinavir/ritonavir Kaletra Protease inhibitors
Ritonavir is also a
cytochrome P450 and P-gp
inhibitor
HIV
Oseltamivir Tamiflu Inhibits viral neuraminidase
and blocks the release of
viral particles from host
cells
Influenza















Carrimycin – Inhibition translation of
mRNA
Macrolide antibiotic











Nitazoxanide Alinia, Nizonide, and
others







Cozaar, others Competitive angiotensin II
receptor type 1 antagonist
Hypertension
Tetrandrine – Calcium channel blocker Hypertension
Spironolactone Aldactone, others Potassium-sparing diuretic Hypertension
Bromhexine Bisolvon, others Increasing lysosomal
activity
Mucolytic
Dornase alfa Pulmozyme Recombinant human
deoxyribonuclease I
Cystic fibrosis
Dexmedetomidine Precedex Selective alpha-2
adrenoceptor agonist
Sedation
Fluoxetine Prozac, others Selective serotonin
reuptake inhibitor
Antidepressant
Table 1. Properties of Repurposed Drugs for COVID-19a
(Continued on next page)
ll
OPEN ACCESS
iScience 23, 101303, July 24, 2020 5
iScience
Review
Drug Brand Name Mechanism of Action Main Indication
Immunosuppressors
Ruxolitinib Jakafi, Jakavi JAK inhibition Rheumatoid arthritis
Tocilizumab Actemra, RoActemra Interleukin-6 receptor
antagonist
Rheumatoid arthritis




























Interferons (IFN) IFN alfa-1b (Pegasys), IFN
alfa-2b (Intron-A), IFN beta-


















P-gp, P-glycoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.
aProperties of repurposed drugs for COVID-19 are comprehensively described elsewhere (Lythgoe andMiddleton, 2020) and




ReviewRecently, dornase alfa as a recombinant human deoxyribonuclease I is considered for clinical trials of pa-
tients with severe COVID-19 who mostly progress to an ARDS condition: hypoxemic respiratory failure
associated with neutrophilia and neutrophil infiltration in the lungs, thick mucus in bronchi, and bronchiec-
tasis (Pottecher et al., 2020). Dornase alfa acts as a mucolytic by cleaving extracellular chromosomal DNA
from neutrophil extracellular traps. Accordingly, using this treatment for patients with ARDS in severe
COVID-19 may lead to mucous plug clearance and accelerated recovery.EMPLOYMENT OF DRUG REPURPOSING APPLICATIONS FOR DEVELOPING ANTIVIRAL
DRUGS
At present, over 40 antiviral agents are accessible for the treatment of viral infections. Unfortunately, the
most commonly used antiviral drugs are accompanied by severe obstacles including insufficient selectivity,
resistance, promotion of latency, toxicity, or experimental difficulties (De Clercq and Li, 2016). Drug6 iScience 23, 101303, July 24, 2020
Figure 2. Procedure of Care for Patients with COVID-19, Including Common Symptoms, Comorbidities,




Reviewrepurposing approaches related to infectious diseases incorporate a variety of applications by harmonizing
key bioinformatics and cheminformatics methods to discover a drug target that could be repurposed in the
combat against a viral pathogen (Turanli et al., 2019). In addition to indisputable cost-effective benefits in
the practice of drug discovery, recycled drugs gain access into clinical trials instantly or are taken up with
compassionate use programs, particularly in the context of untreatable viral diseases or pandemics.
Furthermore, drug repurposing provides an alternative source of data for a novel understanding of meta-
bolic reprogramming in viral infections, as well as the organic compounds with previously unrecognized
antiviral behaviors that are possible to expand in unveiling properties of virus biology (Pizzorno et al.,
2019). In various instances, drug repurposing identifies formerly undiscovered biomolecular networks,
transforming them into novel pharmaceutical targets, even though the determined molecules may not
be implemented into clinical trials (Turanli et al., 2019b).
Over the last decade, the antiviral properties of repurposed drugs have gained considerable attention due
to the lack of targeted treatments for specific emerging viruses (Law et al., 2013). Innumerable technical and
bureaucratic challenges in de novo antiviral drug development have resulted in a very low therapeutic
molecule approval rate, and as such, viral diseases such as hepatitis C and HIV are still without a vaccine.
In recent years, dengue, Ebola, Zika, and coronaviruses have become public health crises, creating an
ongoing demand for immediate and profitable therapeutics solutions by using antiviral drug repurposing
approaches (Boldescu et al., 2017). Particularly, when an epidemic occurs, prompt actions by known drugs
might help to minimize the damage until virus-specific antiviral drugs or vaccines become available. For
instance, niclosamide, a well-known antihelminthic drug, proved its repurposing potential for the treat-
ment of Zika infections (Xu et al., 2016). Another interesting candidate is chloroquine and its derivatives,
which are normally indicated for malaria and have been extensively discussed in terms of their ability of
the possible use for the treatment of COVID-19, as well as other diseases such as connective tissue disor-
ders and some cancers including bladder, breast, colon, and prostate cancers (Cortegiani et al., 2020).
Notably, yet there is no FDA-approved therapy for neither Ebola nor Zika virus, but promising clinical




ReviewDrug repurposing methods are principally based on the analysis of biological data that make it possible to
generate the hypotheses for rediscovery of available compounds for novel solutions in clinical practice and
has been extensively reviewed elsewhere (Pushpakom et al., 2019). Here we summarize the most common
computational drug repurposing approaches, and we detail the in silico drug repurposing studies of the
current global health problem COVID-19.
Computational drug repurposing approaches can be broadly categorized as (1) signature based, (2) mo-
lecular docking, (3) network based, and (4) genome-wide association studies (GWAS). Signature-based
drug repositioning is comparison of the pattern of gene expression profiles of a drug against that of
another drug (i.e., drug-drug comparison), disease (i.e., drug-disease comparison), or clinical phenotype
by using high-throughput omics data (transcriptomic, proteomic, or metabolomic), molecular structures,
or adverse effect profiles (Keiser et al., 2009). Second, molecular docking is a keymethod in structure-based
computational drug repurposing approaches based on predicting the ligand and the target complemen-
tation based on position and relative orientation of one molecule in the binding site of another molecule to
generate a stable complex. Existing information of a receptor target associated with a disease enables re-
searchers to inspect various potential drugs for a range of conditions. Reversely, libraries of compounds
could be screened against receptor targets to investigate unknown interactions to discover candidates
for drug repurposing process (Kitchen et al., 2004). Another key approach for computational drug design
is network-based drug repurposing, which is based on the construction of the biological networks by using
different data types such as gene expression patterns, protein interactions, or disease pathology (Greene
and Voight, 2016). Finally, GWAS seek to determine the differences in genetic material related with com-
mon diseases and accordingly contribute a better understanding to the physiology of the diseases. The
collected knowledge may also assist to define novel targets, a number of which could be allocated among
diseases treated by medicine, and observable characteristics of the disease revealed by GWAS and there-
fore give rise to repurposing of drugs (Sanseau et al., 2012).
In silico drug repurposingmethodologies have accelerated the studies in drug discovery through the use of
data mining approaches, bioinformatics techniques, and predictive models for determining the efficacy
and safety of the drugs. However, there is still a long way to reach the high success rates with repurposed
drugs (e.g., repurposed candidates succeeded 9%–67%, depending on the similarity between indicated
and repurposed therapeutic areas, and the novel molecular entity success rate is 10%) (Hay et al.,
2014; Neuberger et al., 2019). This is presumably attributable to the (1) heterogeneity and incompleteness
of the available data, (2) flexibility and complexity of the entire biological system and pathophysiological
conditions, and (3) lack of reliable experimental data and accurate parameters related to absorption, dis-
tribution, metabolism, excretion (ADME) and toxicity, just to name a few (Brown and Patel, 2018; Ekins
et al., 2007; Zhang et al., 2020a). Future studies should be directed toward obtaining a more improved
test standardization and proof of concept as well as integrating the big and heterogeneous amount of
data into a harmonious workflow. To leverage the benefits, drug repurposing must be performed through
aforethought procedures based on the advanced stage innovation. On account of clinical trials for drug
development, regardless of repositioned drug or novel molecular entity, these are expensive and time
consuming, so basic science methodologies (i.e., improved animal models, accurate toxicology assess-
ment, biomarker identification, and novel targeted delivery technologies) that undertake and reduce the
possibility of hypothesis risk will be essential to increase the success rate of repurposed drugs in the prod-
uct development process (Oprea et al., 2011).IN SILICO DRUG REPURPOSING STUDIES FOR COVID-19
Earlier studies with other viruses of the Coronaviridae family have identified the aforementioned ACE2 re-
ceptor (Li et al., 2003) and RdRp (Imbert et al., 2006), and also coronavirus main protease (Mpro, also called
3CLpro) (Xue et al., 2008) and papain-like protease (PLpro) (Kilianski et al., 2013), as candidate drug targets.
An appealing biological target for coronaviruses is the main protease by virtue of its crucial role in viral
gene expression and replication. Taking this into account, Zhang et al. published the crystal structures
of the Mpro of SARS-CoV-2 and docked it with a pyridone-containing a-ketoamide inhibitor. The assess-
ment of pharmacokinetic results onmice revealed a noticeable lung tropism, which promises this lead com-
pound as a suitable candidate for further drug development process (Zhang et al., 2020b). In addition, in-
hibiting the function of this enzyme blocks the viral life cycle. The absence of homologs in humans means
that Mpro is an attractive non-toxic target for antiviral drug design that is not prone to off-target effects.




Reviewidentification of candidate compounds from existing drugs targeting SARS-CoV-2, gaining the attention of
other research teams. For instance, Jin et al. developed a data-driven drug repositioning framework, which
applies both structure-based drug design and high-throughput screening approaches to inform putative
drug candidates against the main protease of SARS-CoV-2. In silico screening followed by cell-based vali-
dation indicated that ebselen, a drug with anti-inflammatory, antioxidant, and cytoprotective activities,
may be repurposed to treat COVID-19 (Jin et al., 2020). These studies audibly support the view that an anti-
viral compound targeting Mpro could provide a strong defense against coronavirus-associated diseases.
There are considerable opportunities in systematically investigating the dynamic interactions between host
and SARS-CoV-2 to identify target human proteins for repurposing known drugs. Targeting the host-virus
interactions, which are essential in the virus life cycle and demonstrate less tendency of mutational resis-
tance, might show effectiveness in developing robust treatment options for viral infections (Kaufmann
et al., 2018). However, lack of data of the pathophysiology of the SARS-CoV-2 infection restrains the devel-
opment of small molecule candidates based on the host-targeted strategies. Systematically mapping in-
teractions between SARS-CoV-2 proteins and human proteins revealed that inhibitors of mRNA translation
and regulators of the Sigma1 and Sigma2 receptors might have antiviral activity (Gordon et al., 2020). Even
though the role of action of compounds targeting the Sigma receptors is not well defined, receptor ligands
and their mechanisms involved in immune modulator activity are considered promising antiviral targets
and numerous approved compounds hold the potential to be repurposed (Gordon et al., 2020).
Characterization of viral evolution and the alterations in host cell metabolism through the use of single-cell viral
metagenomic studiesmight shed light on themechanisms of viral infections, including determination of themo-
lecular signatures associated with virus-induced pathologies (Xu and Zhao, 2018). A computation-based meth-
odology, namely, Viral-Track, applied to bronchoalveolar lavage samples from patients with severe and mild
COVID-19 unveils a remarkable impact of the virus on the immune system of the patients with severe condition
compared with those with mild condition, including replacement of the tissue-resident alveolar macrophages
with recruited inflammatory monocytes, neutrophils, and macrophages and an altered CD8+ T cell cytotoxic
response (Bost et al., 2020). Further efforts on large-scale datasets will lead to reveal many mechanistic aspects
of viral infections yet to be resolved and will help to develop more efficient therapy strategies.CONCLUSION
Due to urgent need, we posit that drug repurposing is the leading method for drug discovery against
COVID-19, whether through wet laboratory techniques and/or system biology approaches. Available clin-
ical trials at both ClinicalTrials.gov (https://clinicaltrials.gov/) and WHO Solidarity includes the investiga-
tion of previously approved drugs for different indications. Taking into account that in the past two decades
three coronaviruses emerged from animal reservoirs (the virus family that used to cause mild to moderate
upper respiratory tract illnesses) and each one of them was cause of global concern, a common treatment
may prevent coronavirus to become another lethal annual re-occurrent threat on top of seasonal influenza.
COVID-19, similar to all other pandemics throughout history, does not discriminate in terms of geopolitical
borders, nationality, religion, creed, or color. A reliable forecasting of impact size and time of the ongoing
COVID-19 pandemic, whether by epidemiological models or artificial intelligence-inspired methods,
would be helpful in efficient management of SARS-CoV-2 repercussions. Accordingly, an international
effort and unanimity are crucial to diminish the destructive effect of the COVID-19 pandemic on health
care systems, casting a shadow of doubt on the futures of many nations. In spite of swift progress in viro-
logical and epidemiological knowledge of SARS-CoV-2, therapeutic challenges escalated rapidly as well.
Daily changes in the number of studies and complementary results of ongoing clinical trials, including suc-
cesses and failures, indicate the promising outcome in close future.SEARCH STRATEGY AND SELECTION CRITERIA
Data for this review were identified by searches of PubMed, Google Scholar, and references from relevant
articles using the search terms ‘‘SARS-CoV-2,’’ ‘‘COVID-19,’’ ‘‘drug repurposing,’’ ‘‘antiviral therapy,’’
‘‘clinical trials,’’ ‘‘COVID-19 therapy,’’ and ‘‘pandemic.’’ Only articles published in English were included.SUPPLEMENTAL INFORMATION
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